Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 19/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124236 | 0.88 | NOTUM (0.44) | IDO1KCNH2CYP2C9CYP3A4 | |
| SCHEMBL22397636 | 0.80 | IDO1 (0.47) | IDO1KCNH2CYP2C9CYP3A4 | |
| SCHEMBL29133297 | 0.76 | KDM4E (0.38) | IDO1KCNH2USP30 | |
| SCHEMBL6124262 | 0.76 | IDO1 (0.49) | IDO1KCNH2CYP2C9CYP3A4 | |
| SCHEMBL6124268 | 0.76 | IDO1 (0.34) | IDO1KCNH2CYP2C9CYP3A4 | |
| SCHEMBL22397599 | 0.74 | IDO1 (0.55) | IDO1KCNH2CYP2C9CYP3A4 | |
| SCHEMBL22397510 | 0.74 | IDO1 (0.60) | IDO1KCNH2CYP2C9CYP3A4 | |
| SCHEMBL288294 | 0.74 | IDO1 (0.37) | IDO1KCNH2USP30 | |
| SCHEMBL288301 | 0.74 | KDM4A (0.38) | IDO1KCNH2USP30 | |
| SCHEMBL6124234 | 0.73 | CYP11B1 (0.39) | IDO1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207759-A1 | NEW PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A (ES) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207759-A1 | NEW PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNA1G, ADRB2 | IDO1 2070/4885KCNH2 131/4885CYP2C9 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.